MET and non-small cell lung carcinoma: Despite the initial promising response to EGFR-TKIs in majority of NSCLC patients harboring sensitizing EGFR mutations [43], [44], most patients eventually relapse due to the emergence of acquired resistance such as the EGFR T790M mutation or MET amplification, both accounting for about 70% of the acquired resistance [4].